Rachel Hau­r­witz & Jen­nifer Doudna


Inc. (USA) - - 100 FF - —Kevin J. Ryan

In the fu­ture, deadly dis­eases will be snipped from your DNA like lines of bad code. At least that’s how the Univer­sity of Cal­i­for­nia at Berke­ley bio­chem­istry pro­fes­sor (Doudna) and her former-stu­dent-turned-CEO (Hau­r­witz) en­vi­sion it. Doudna’s re­search team at Berke­ley pub­lished the first pa­per il­lus­trat­ing Crispr’s gene-edit­ing abil­i­ties back in 2012, and then spun it out into the Berke­ley-based com­pany, which now has 50 em­ploy­ees—half of whom are fe­male—and more than $40 mil­lion in fund­ing. The con­tro­ver­sial goal, which the founders hope to ac­com­plish within five to 10 years, is to re­lease FDA-ap­proved ther­a­pies that could at­tack ev­ery­thing from can­cer to cys­tic fi­bro­sis, as well as to en­gi­neer malaria-re­sis­tant mos­qui­toes. First, though, they have to sur­vive their on­go­ing pa­tent dis­pute with MIT.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.